Lou S, et al. - Authors evaluated the efficacy and safety of combination therapy with parathyroid hormone analogs and antiresorptive agents therapy for osteoporosis. They searched MEDLINE, EMBASE, and Cochrane Library databases from inception to May 1, 2018, for relevant randomized controlled trials (RCTs) with a ≥ 6-month duration period that reported on adults with osteoporosis treated with combination therapy vs monotherapy. A total of 19 studies representing 2,177 patients were included in the analysis. Findings suggested superiority of combination therapy to monotherapy regarding improvement of the lumbar spine and total hip bone mineral density, without risk of serious adverse events among patients with osteoporosis. They also noted an advantage of combination therapy over monotherapy on fracture risk reduction.